Korean J Nucl Med.  1999 Feb;33(1):11-27.

Somatostatin Receptor Scintigraphy

Abstract

Peptide imaging is a new diagnostic modality in nuclear medicine. 111In-pentetreotide (OctreoscanR) is the first commercially available peptide radiopharmaceutical. This review article presents the
RESULTS
of previous studies using 111In-pentetreotide for several disease states, including neuroendocrine tumors, breast cancer and malignant lymphoma. The use of hand-held probe during surgery and the preliminary
RESULTS
of radiotherapy using radiolabeled somatostatin analogues are also reviewed. It can be concluded that somatostatin receptor scintigraphy is a promising diagnostic tool for localizing primary tumors that express receptors for somatostatin, staging secondary spread of tumor tissue, following up after therapy and identifying patients who may benefit from therapy with unlabelled or rediolabeled octreotide. The somatostatin receptor imaging will stimulate the development of new radiopharmaceuticals for other receptors and enhance the therapeutic use of radiolabeled peptides.

Keyword

In-111 pentetreotide; Soatostatin receptors; Radionuclide imaging; Neuroendocrine tumors

MeSH Terms

Breast Neoplasms
Humans
Lymphoma
Neuroendocrine Tumors
Nuclear Medicine
Octreotide
Peptides
Radionuclide Imaging*
Radiopharmaceuticals
Radiotherapy
Receptors, Somatostatin*
Somatostatin*
Octreotide
Peptides
Radiopharmaceuticals
Receptors, Somatostatin
Somatostatin
Full Text Links
  • KJNM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr